PDCD1 and diffuse large B-cell lymphoma: The mechanism of resistance to anti‐PD‐1/PD‐L1 therapy is unclear but might be because the tumor immune microenvironment (TIME) in DLBCL is not simple, and the interaction of very complex factors is intertwined.